Leach 1995.
Methods | Randomized controlled trial Generation of allocation sequence: method not reported Allocation concealment: not specified Blinding: double blind Inclusion of all randomized participants: 147/150 (98%) received all 3 doses; 127 children (84.7%) were located and followed in the second year Length of follow up: 9 months in first year, then 18 weeks in the second year |
|
Participants | 150 infants Inclusion criteria: age 6 to 11 months Exclusion criteria: none stated |
|
Interventions | 1. 3 doses of SPf66 on days 0, 30, and 180 in 4 groups: 1 mg Colombian vaccine (25 participants); 0.5 mg Colombian vaccine (25 participants); 1 mg American vaccine (25 participants); 0.5 mg American vaccine (25 participants) 2. Inactivated polio vaccine (50 participants) | |
Outcomes | 1. Incidence of first episode of malaria, after 2 and 3 doses of vaccine (case definition: fever of ≥ 37.5 ºC and Plasmodium falciparum parasitaemia of ≥ 6000/µL) 2. Total number of episodes of malaria 3. Death 4. Severe anaemia 5. Cerebral malaria 6. Admission to hospital with malaria 7. Antibodies to SPf66 by ELISA 8. Adverse events | |
Notes | Location: villages near Basse, The Gambia Date: 1993 to 1995 Method of surveillance: active by home visits every 2 weeks during rainy season; passive by attendance at clinic Adverse effects assessed on days 1, 2, and 6 |